Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia. Cancer 1992 Jan 15;69(2):410-2
Date
01/15/1992Pubmed ID
1370212DOI
10.1002/1097-0142(19920115)69:2<410::aid-cncr2820690222>3.0.co;2-vScopus ID
2-s2.0-0026542063 (requires institutional sign-in at Scopus site) 27 CitationsAbstract
In four patients with Philadelphia chromosome-positive (Ph1) chronic myelogenous leukemia (CML), bone marrow hypoplasia (three patients) and aplasia (one patient) developed during or after therapy with either alpha-interferon (IFN) or gamma-IFN. The predominant clinical characteristic of this complication was protracted pancytopenia, which required 2 to 5 months recovery time after treatment and did not resolve in one patient. Bone marrow cytogenetic analysis in two of the patients demonstrated 100% Ph1 metaphases despite the profound bone marrow suppression. Overall, this complication was uncommon, occurring in less than 2% of the patients with CML treated with various IFN. The possible underlying causes include previous therapy with alkylating agents, lack of "reservoir" or normal stem cells, or pronounced sensitivity of the malignant cell clone to the suppressive effect of IFN.
Author List
Talpaz M, Kantarjian H, Kurzrock R, Gutterman JUAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAnemia, Aplastic
Bone Marrow Diseases
Bone Marrow Examination
Female
Humans
Interferons
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Middle Aged